Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results

Fernández-Cuadros, Marcos Edgar; Albaladejo-Florín, María Jesús; Álava-Rabasa, Sandra; Usandizaga-Elio, Isabel; Jimenez, Dolores; Peña-Lora, Daiana; Neira-Borrajo, I.; López-Muñoz, María Jesús; Rodríguez-de-Cía, Javier; Pérez-Moro, Olga Susana

doi:10.1007/s42399-020-00374-1

Cited by 28 publications

(35 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical improvement observed in our preliminary results 12 and now in this case-control study con rms the promising utility of Ozone in the management of COVID-19 pandemic, as stated by some other authors 11,[15][16][17] .…”

Section: Discussionsupporting

confidence: 88%

“…Only one CT has published its results (Ozone autohemotherapy), while the others are still recruiting patients 4,5 . There subsides the importance of the Study; there is no report on the literature of the effectiveness of rectal Ozone, apart from our preliminary results recently published (four cases) 12 . This study presents the largest sample of COVID-19 patients treated by rectal Ozone insu ation in a case-control design.…”

Section: Discussionmentioning

confidence: 72%

“…Recently, our study Group has presented the preliminary results of 4 mild-severe COVID-19 patients treated by rectal Ozone, with very promising results on the management of SARS-Cov-2 infection 12 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Compassionate use of rectal Ozone (O3) in severe COVID-19 pneumonia: a case-control study.

Fernández-Cuadros

Albaladejo-Florín

Álava-Rabasa

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Objectives: To evaluate effect of rectal Ozone in severe COVID-19 pneumonia and to compare to Standard-of-care (SOC). Material and Methods: In a case-control study, 14 patients with severe bilateral COVID-19 pneumonia (positive RT-PCR), treated with SOC and rectal Ozone, were evaluated before-and-after treatment and compared with SOC (14 patients) in a 10 day follow-up period. Ozone-protocol consisted of 8 sessions (1 session/day) of intra-rectal Ozone, (150mL volume, 35mg/ml concentration [5.25mg total dose]). The SOC-protocol included O 2- supply, antivirals (Remdesivir), corticosteroids (Dexamethasone/Metilprednisolone), monoclonal antibodies (Anakinra/Tocilizumab), antibiotics (Azytromicine), anticoagulants (Enoxaparine) and hyperimmune serum (if necessary). Primary outcome variables: a) clinical (O 2- saturation and O 2- supply); b) biochemical (Lymphocyte count, Fibrinogen, D-Dimer, Urea, Ferritin, LDH, IL-6 and CRP); c) radiological Taylor Scale. Secondary outcome variables: a) hospitalization length-of-stay, b) mortality-rate. Results: At baseline, Ozone/SOC-groups were not different on age, comorbidities, O 2 -saturation and O 2 -supply. Patients in Ozone-Group improved O 2- saturation and decrease O 2- supply. SOC maintained O 2- saturation and required more O 2- supply. Lymphocyte-count improved only in Ozone-group and with statistical difference (p<0.05). Biomarkers of inflammation (Fibrinogen, D-Dimer, Urea, LDH, CRP and IL-6) decreased in both groups, but only significantly in favor of Ozone-group (p<0.05). Ferritin showed a significant decrease in the Ozone-group but an increase on the SOC-Group. Radiological pneumonitis decreased on both groups but the decrease was only significant in the Ozone-Group (p<0.0001). Mortality and length-of-stay, although not significant, were inferior in Ozone-Group. Conclusion: Compassionate use of Rectal Ozone improved O 2 -saturation, reduced O 2 -supply, decreased inflammation biomarkers and improved Taylor’s radiological scale significantly when compared to SOC-Group. Mortality and length-of-stay was inferior in the Ozone-group, but this difference was not significant.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 72%

See 1 more Smart Citation

Compassionate use of rectal Ozone (O3) in severe COVID-19 pneumonia: a case-control study.

Fernández-Cuadros

Albaladejo-Florín

Álava-Rabasa

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…At the moment, only 4 papers including case series of patients affected by COVID‐19 and treated with ozone therapy are present in the indexed and peer reviewed scientific literature. In particular Fernández‐Cuadros ME et al 38 reported a prospective quasi‐experimental before‐and‐after study on four severe COVID‐19 patients treated by rectal ozone administration, Hernández et al 39 described three patients with COVID‐19 pneumonia treated by 1–4 sessions of oxygen–ozone (O₂–O₃) therapy, Zheng et al 40 portrayed two severe cases with COVID‐19 received ozone therapy. Finally, Franzini et al reported a larger study on 50 SARS‐COV2 positive elderly patients suffering from acute respiratory disease syndrome treated with four cycles of O 2 –O 3 .…”

Section: Discussionmentioning

confidence: 99%

Ozone as adjuvant support in the treatment of COVID‐19: A preliminary report of probiozovid trial

Araimo

Imperiale

Tordiglione

et al. 2020

Journal of Medical Virology

104

View full text Add to dashboard Cite

The evaluation of new therapeutic resources against coronavirus disease 2019 (COVID‐19) represents a priority in clinical research considering the minimal options currently available. To evaluate the adjuvant use of systemic oxygen‐ozone administration in the early control of disease progression in patients with COVID‐19 pneumonia. PROBIOZOVID is an ongoing, interventional, randomized, prospective, and double‐arm trial enrolling patient with COVID‐19 pneumonia. From a total of 85 patients screened, 28 were recruited. Patients were randomly divided into ozone‐autohemotherapy group (14) and control group (14). The procedure consisted in a daily double‐treatment with systemic Oxygen–ozone administration for 7 days. All patients were treated with ad interim best available therapy. The primary outcome was delta in the number of patients requiring orotracheal‐intubation despite treatment. Secondary outcome was the difference of mortality between the two groups. Moreover, hematological parameters were compared before and after treatment. No differences in the characteristics between groups were observed at baseline. As a preliminary report we have observed that one patient for each group needed intubation and was transferred to ITU. No deaths were observed at 7–14 days of follow up. Thirty‐day mortality was 8.3% for ozone group and 10% for controls. Ozone therapy did not significantly influence inflammation markers, hematology profile, and lymphocyte subpopulations of patients treated. Ozone therapy had an impact on the need for the ventilatory support, although did not reach statistical significance. Finally, no adverse events related to the use of ozone‐autohemotherapy were reported. Preliminary results, although not showing statistically significant benefits of ozone on COVID‐19, did not report any toxicity.

show abstract

“…The effectiveness of rectal O3 insufflation was evaluated in a recent study that included four patients with severe COVID-19 pneumonia. Improved oxygen saturation was noted after 5 sessions of treatment, together with reduced levels of biomarkers of inflammation [ 8 ]. In the following cases, we used O3 therapy as a potential treatment, based on our knowledge about its ability to treat hypoxia and its antiviral properties.…”

Section: Introductionmentioning

confidence: 99%

Old Treatment for a New Disease: Can Rectal Ozone Insufflation Be Used for COVID-19 Management? A Case Report

Hendawy

Mosallam

Abuelnaga

et al. 2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

COVID-19 is a newly discovered deadly disease with no proven definitive treatment until now. It is now proved that it can affect different body organs which necessitate intensive care management. Ozone (O3) therapy was used before for treating various viral infections like hepatitis B, human immune deficiency virus (HIV), and Ebola viruses. O3 also can manage hypoxia and increase tissue oxygenation, besides its anti-inflammatory and immunomodulatory properties which may have an important role in the management of cytokine storm. We used rectal O3 insufflation therapy assuming that it may have a beneficial role in the management of COVID-19 disease. Two sessions of rectal O3 therapy were given to a 60-year-old female patient who was confirmed COVID-19 positive. Before applying O3 therapy, she was hypoxic (sPO2:90%) despite mechanical ventilation with high fraction inspired oxygen (FiO2:90%). After therapy, she was markedly improved and discharged to the inpatient ward and then discharged home on day 10 post-admission. Another 40-year-old male patient who was confirmed COVID-19 positive and was home isolated received one session of O3 therapy. Before therapy, he was hypoxic (sPO2:85% on room air and 95% with O2 face mask 5 L/min). The patient showed gradual improvement over the next 3 days after therapy and becomes oxygen-independent (sPO2 became 94–97% on room air). No adverse effects were noticed in both cases. Rectal O3 insufflation can be used safely as adjuvant management for patients with COVID-19 disease.

show abstract

Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results

Cited by 28 publications

References 19 publications

Compassionate use of rectal Ozone (O3) in severe COVID-19 pneumonia: a case-control study.

Compassionate use of rectal Ozone (O3) in severe COVID-19 pneumonia: a case-control study.

Ozone as adjuvant support in the treatment of COVID‐19: A preliminary report of probiozovid trial

Old Treatment for a New Disease: Can Rectal Ozone Insufflation Be Used for COVID-19 Management? A Case Report

Contact Info

Product

Resources

About